GlaxoSmithKline logoMaking a difference every day - Sustainability in Environment, Helath and Safety Report 2003
Corporate Responsibility Report 2003Download this Report
  EHS Home
  About this Report
  Scope
  Executive Statements
  Framework
  Vision and policies
  Planning
  Organisation
  Management Systems
  Programmes
  Audit
  Stakeholder Communication
  Reward and Recognition
  Issues
  Performance
  Verification Statement
  Global Reporting Initiative Content Index
  Index
   

 

Planning

Planning
The EHS Plan for Excellence
Targets

Strategy
GlaxoSmithKline's EHS strategy of continuous improvement supports corporate social responsibility and encourages a sustainable business culture. It is based on the principles of the GlaxoSmithKline Spirit:

  • Passion: GlaxoSmithKline works to protect people and the environment in a company dedicated to improving the quality of human life.

  • Sense of Urgency: The absence of EHS programmes could endanger the lives and health of GlaxoSmithKline employees and the quality of the environment.

  • Entrepreneurial: We look for new ways of working throughout the organisation - from research & development to manufacturing and sales - in order to improve our efficiency.

  • Innovation: We want to be a leader in the way we manage our EHS responsibilities by adopting new approaches to chemistry, manufacturing processes, waste treatment, safe working, transparent reporting and everything we do.

  • Integrity: GlaxoSmithKline includes responsibility for good environment, health and safety management in our definition of integrity. It is fundamentally the right thing to do.

The EHS strategy also aligns with GlaxoSmithKline's five business drivers:

People
The single greatest source of competitive advantage is GlaxoSmithKline's people. It is vital that we protect the health and safety of employees, contractors, visitors and others affected by our operations. We will design our facilities and processes, conduct assessments and provide training in order to eliminate work-related risks to safety and health. We will focus on employee health enhancement, mental well-being, causes of absence and methods of rehabilitation in order to have a productive and resilient work force.

New Product Portfolio
Our new products are carefully designed to help millions of people around the world live longer, healthier and happier lives. To treat disease, the products must have biological activity and as a result have potential EHS risks and impacts throughout their life-cycle i.e. from raw material acquisition to research and development and manufacturing through to patient use and disposal. We will apply the principles of product stewardship throughout our organisation to deliver positive EHS benefits and minimise risks to our business, people and the environment. Product stewardship encompasses the assessment of the health, safety (excluding patient safety, which is assessed separately), and environmental risks created during all stages of the product's life-cycle and in particular at the key decision stages in research & development. We will also apply product stewardship principles to our contract manufacturers and key suppliers.

Product Commercialisation
Environment, health and safety play an important role in commercialising products. By integrating environment, health and safety planning into decision-making on manufacturing processes, packaging design and product labelling, we help differentiate our products and protect and extend product life-cycles. By fully embracing EHS principles, the sales organisation can minimise the cost of motor vehicle accidents and maximise the productivity of sales and distribution staff while optimising their environmental efficiency.

Global Competitor
As a global competitor, GlaxoSmithKline seeks to be a leader in EHS within the pharmaceutical and consumer health sectors by applying best business processes globally and fostering a culture of continuous improvement. As a global corporate citizen, we will demonstrate our commitment to corporate responsibility by implementing global standards, guidelines, targets and management systems and by auditing our programmes and reporting publicly and openly on performance. We will seek dialogue with external stakeholders and consider their views when developing our approaches to EHS management.

Operational Excellence
GlaxoSmithKline's operations must achieve legal compliance with EHS regulations. In the spirit of operational excellence they must also continuously improve performance particularly in the areas of accident and occupational illness prevention, waste minimisation and emissions reductions. We seek to integrate EHS aspects into business processes, such as capital planning, decision-making, purchasing, training and communications.

 
Previous

Next